Clinical Trials

Hormone-Refractory Prostate Cancer (HRPC) Clinical Trial

Trial Number—AT-101-CS-202

An open-label, multicenter phase I/II trial assessing the safety and efficacy of AT-101, a new treatment for prostate cancer, in combination with docetaxel and prednisone in men with HRPC.

Where is this study being conducted?

This trial is currently being conducted at several study sites within the United States.

Who is conducting the trial?

This trial is being sponsored by Ascenta Therapeutics, Inc.

Who can participate?

Men whose prostate-specific antigen (PSA) levels are rising despite treatment to drastically reduce testosterone levels.

Men with confirmed metastatic disease and adequate blood, liver, and renal function.
Patients who can swallow medication.

Patients with brain metastases are not eligible.
Patients are not permitted to take other anticancer medications or antiandrogen hormonal therapy during the trial.

What is AT-101?

AT-101 activates a pathway inside cancer cells resulting in the death of those cells. It is given by mouth in the form of pills.

What is docetaxel?

Docetaxel is a form of chemotherapy that nonspecifically kills cells that are rapidly dividing in the body, including cancer cells. It is given once every 3 weeks through an intravenous (IV) infusion over the course of 1 hour.

What is prednisone?

Prednisone is a steroid that decreases inflammation. It is given as a pill or liquid by mouth with food.

What do I do if I am interested in participating in this clinical trial?

Contact your physician. Your physician will be able to advise you about participating.

Trial Identification Number

NCT00286793